239 related articles for article (PubMed ID: 20591913)
1. FISH assay development for the detection of p16/CDKN2A deletion in malignant pleural mesothelioma.
Chung CT; Santos Gda C; Hwang DM; Ludkovski O; Pintilie M; Squire JA; Tsao MS
J Clin Pathol; 2010 Jul; 63(7):630-4. PubMed ID: 20591913
[TBL] [Abstract][Full Text] [Related]
2. The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
Kulduk G; Ekinci Ö; Toker G; Demirci U; Özaydın E; Akyürek N; Memiş L
Pathol Res Pract; 2019 Jun; 215(6):152377. PubMed ID: 30885529
[TBL] [Abstract][Full Text] [Related]
3. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
4. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
[TBL] [Abstract][Full Text] [Related]
5. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
6. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.
Chiosea S; Krasinskas A; Cagle PT; Mitchell KA; Zander DS; Dacic S
Mod Pathol; 2008 Jun; 21(6):742-7. PubMed ID: 18327208
[TBL] [Abstract][Full Text] [Related]
8. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
9. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
10. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
[TBL] [Abstract][Full Text] [Related]
11. Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations.
Nabeshima K; Matsumoto S; Hamasaki M; Hida T; Kamei T; Hiroshima K; Tsujimura T; Kawahara K
Diagn Cytopathol; 2016 Sep; 44(9):774-80. PubMed ID: 27219841
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
13. p16 FISH deletion in surface epithelial mesothelial proliferations is predictive of underlying invasive mesothelioma.
Hwang H; Tse C; Rodriguez S; Gown A; Churg A
Am J Surg Pathol; 2014 May; 38(5):681-8. PubMed ID: 24503757
[TBL] [Abstract][Full Text] [Related]
14. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
[TBL] [Abstract][Full Text] [Related]
15. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of NF2 hemizygous loss detected by fluorescence in situ hybridization in diagnosing pleural mesothelioma in tissue and cytology material: A multi-institutional study.
Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Kasai T; Kushitani K; Takeshima Y; Hiroshima K; Iwasaki A; Nabeshima K
Lung Cancer; 2023 Jan; 175():27-35. PubMed ID: 36442384
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
Dacic S; Kothmaier H; Land S; Shuai Y; Halbwedl I; Morbini P; Murer B; Comin C; Galateau-Salle F; Demirag F; Zeren H; Attanoos R; Gibbs A; Cagle P; Popper H
Virchows Arch; 2008 Dec; 453(6):627-35. PubMed ID: 18958493
[TBL] [Abstract][Full Text] [Related]
18. The diagnostic utility of p16 FISH and GLUT-1 immunohistochemical analysis in mesothelial proliferations.
Monaco SE; Shuai Y; Bansal M; Krasinskas AM; Dacic S
Am J Clin Pathol; 2011 Apr; 135(4):619-27. PubMed ID: 21411785
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
Minami K; Jimbo N; Tanaka Y; Hokka D; Miyamoto Y; Itoh T; Maniwa Y
Virchows Arch; 2020 Mar; 476(3):469-473. PubMed ID: 31667596
[TBL] [Abstract][Full Text] [Related]
20. 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
Takeda M; Kasai T; Enomoto Y; Takano M; Morita K; Kadota E; Nonomura A
Pathol Int; 2010 May; 60(5):395-9. PubMed ID: 20518890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
